In animal studies, the use of perfluorocarbons (FP-43) has been shown to enhance the reabsorption of bubbles and the solubility of gases, thereby decreasing both the neurologic and cardiovascular complications of systemic and coronary venous air embolism. These benefits, however, have not been validated in humans.